अApnaFunda
Menu

CAPLIN POINT LABORATORIES LTD (CAPLIPOINT)

Health Technology · Pharmaceuticals: Major · figures to Nov '26

Quality scoreHow the business itself ranks against its sector peers on profitability, 3-year growth and leverage. 50 is the middle of the sector.85 / 100
Profitability 88Growth 67Balance sheet 100
Momentum scoreHow strong the recent trend is: 3-month price change, 12-month improvement in earnings and the rise in FII + DII holding, among companies above ₹500 cr.48 / 100
Price 53Earnings 45FII/DII 46

Passes these screensQuality CompounderDebt-light & profitableConsistent compounders

Compare withSUN PHARMACEUTICAL INDUSTRIESDIVIS LABORATORIESTORRENT PHARMACEUTICALS

Share price

Closing priceAdjusted for splits and bonus issues.

₹2,502.5 latest close · −1.4% over the last 90 sessions

₹2,200₹2,400₹2,600₹2,800Jul 3Jul 29Aug 24Sep 17Oct 14Nov 9 ₹2,200₹2,400₹2,600₹2,800Jul 3Sep 4Nov 9

₹2,502.5 month-end · +31.0% over 12 months

₹1,500₹2,000₹2,500Nov '25Jan '26Apr '26Jun '26Sep '26Nov '26 ₹1,500₹2,000₹2,500Nov '25May '26Nov '26

₹2,502.5 month-end · +99.4% over 3 years

₹1,500₹2,000₹2,500Nov '23Jun '24Jan '25Sep '25Apr '26Nov '26 ₹1,500₹2,000₹2,500Nov '23May '25Nov '26

₹2,502.5 month-end · +589.1% since Jan '19

₹1,000₹2,000Jan '19Aug '20Mar '22Sep '23Apr '25Nov '26 ₹1,000₹2,000Jan '19Dec '22Nov '26

52-week range ₹1500.30 to ₹2990.00 · 1-year volatility 34.1%

Was the rally earned?

+31%share price, 1 yearEarnings and multiple

Both mattered.

  • Per-share earnings added 19 points and the multiple added 12 points (P/E 25.7x to 28.6x).
  • The share count barely moved.
Net profit growth: +18 pts. Points of the price return explained by net profit growing (or shrinking).+18 ptsNet profit growthP/E change: +12 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.+12 ptsP/E changeShare count change: 0 pts. Points of the price return explained by the share count changing. More shares count against the price.0 ptsShare count changeShare price: +31%+31%Share priceNet profit growth: +18 pts. Points of the price return explained by net profit growing (or shrinking).+18ProfitP/E change: +12 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.+12P/EShare count change: 0 pts. Points of the price return explained by the share count changing. More shares count against the price.0SharesShare price: +31%+31%Share price
Net profit growth+18 ptsNet profit rose about 17%, which lifts the price.
P/E change+12 ptsThe P/E rose from 25.7x to 28.6x, which lifts the price.
Share count change0 ptsShare count was little changed. More shares would count against the price.
+99%share price, 3 yearsEarnings-driven

Mostly yes.

  • Per-share earnings added 82 points to the rise, while the multiple moved less (P/E 25.3x to 28.6x).
  • The share count barely moved.
Net profit growth: +82 pts. Points of the price return explained by net profit growing (or shrinking).+82 ptsNet profit growthP/E change: +18 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.+18 ptsP/E changeShare count change: 0 pts. Points of the price return explained by the share count changing. More shares count against the price.0 ptsShare count changeShare price: +99%+99%Share priceNet profit growth: +82 pts. Points of the price return explained by net profit growing (or shrinking).+82ProfitP/E change: +18 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.+18P/EShare count change: 0 pts. Points of the price return explained by the share count changing. More shares count against the price.0SharesShare price: +99%+99%Share price
Net profit growth+82 ptsNet profit rose about 76%, which lifts the price.
P/E change+18 ptsThe P/E rose from 25.3x to 28.6x, which lifts the price.
Share count change0 ptsShare count was little changed. More shares would count against the price.
+234%share price, 5 yearsEarnings-driven

Mostly yes.

  • Per-share earnings added 195 points to the rise, while the multiple moved less (P/E 23.4x to 28.6x).
  • The share count fell 3%.
Net profit growth: +189 pts. Points of the price return explained by net profit growing (or shrinking).+189 ptsNet profit growthP/E change: +39 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.+39 ptsP/E changeShare count change: +6 pts. Points of the price return explained by the share count changing. More shares count against the price.+6 ptsShare count changeShare price: +234%+234%Share priceNet profit growth: +189 pts. Points of the price return explained by net profit growing (or shrinking).+189ProfitP/E change: +39 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.+39P/EShare count change: +6 pts. Points of the price return explained by the share count changing. More shares count against the price.+6SharesShare price: +234%+234%Share price
Net profit growth+189 ptsNet profit rose about 165%, which lifts the price.
P/E change+39 ptsThe P/E rose from 23.4x to 28.6x, which lifts the price.
Share count change+6 ptsShare count fell 3%, which lifts the price.
What do "pts" mean?

"pts" are percentage points of the share price return. The parts add up to the total shown for each period. Because price = P/E × net profit ÷ share count, higher profit pushes the price up, a higher P/E pushes it up, and more shares push it down.

Example: if the price rose 34% and profit growth accounts for +58 pts while a lower P/E accounts for -24 pts, then 58 - 24 = 34. The +58 is not the profit growth rate itself: it is the part of the price move that profit growth explains.

Net profit is trailing twelve months as reported with a 60-day lag.

Compare this with SUN PHARMACEUTICAL INDUSTRIES

How rough has the ride been?

Maximum drawdown-57.5%recovered 2020-08
1-year volatility34.1%annualised
Beta vs sector index1.323-year daily, correlation 0.48
Volume spikes3last 90 sessions, 5x the 50-day median

Drawdown from peak

0%−20%−40%2020202120222023202420252026−47.7% 0%−20%−40%2020202220242026−47.7%
Largest drawdowns

-57.5% (2019-06 peak to 2020-03 low, recovered 2020-08)

-42.1% (2024-12 peak to 2026-03 low, recovered 2026-06)

-38.9% (2021-09 peak to 2023-03 low, recovered 2023-08)

Most recent volume spikes

2026-09-24: 13.5x the 50-day median, price +2.6% that day

2026-09-03: 9.4x the 50-day median, price +4.6% that day

2026-09-01: 22.3x the 50-day median, price +7.7% that day

Beta is the slope of daily returns against a market-cap-weighted index of the sector's other listed companies, built from today's constituents (so it excludes companies no longer listed).

Is it expensive against its own past and its peers?

28.6xP/E todayNear its historic high
Against its own history82nd percentile
CheapestMedian 21.1xDearest

Usual range 15.1x to 30.0x since 2019-01.

Against Health Technology28.6x vs 37.0x
This company
28.6x
Sector median
37.0x

23% below the Health Technology median.

11.0x21.8x32.7x43.5xJan '19Aug '20Mar '22Oct '23May '25Nov '2611.0x21.8x32.7x43.5xJan '19Sep '21May '24Nov '26
P/E (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

The chart loads when you open this tab.

P/B (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

The chart loads when you open this tab.

P/S (this company)10th to 90th percentile of its own historyIts medianHealth Technology median
How to read this

Shaded band: 10th to 90th percentile of the company's own P/E history; dotted line: its median; orange line: sector median (companies with a positive multiple, at least 5 in the sector).

Sector figures are built from today's listed companies, so they exclude companies that are no longer listed.

All terms explained in the glossary →

How Health Technology is valued

Where does it rank among Health Technology peers?

Each cell is the company's percentile rank among its Health Technology peers (non-financial companies) that month.
Darker is better-ranked.
Rows marked ↓ are inverted (lower debt, shorter cash cycle and a lower P/E rank higher).

Where it ranks today

  • ROCE80th▼ 3 pts vs a year ago
  • Op. margin97thflat vs a year ago
  • Revenue growth61st▼ 7 pts vs a year ago
  • EPS growth62ndflat vs a year ago
  • Debt/equity ↓72nd▲ 3 pts vs a year ago
  • Cash cycle ↓39thflat vs a year ago
  • P/E ↓65th▲ 4 pts vs a year ago
  • 12M momentum69th▲ 15 pts vs a year ago

Rank history

ROCE
Op. margin
Revenue growth
EPS growth
Debt/equity ↓
Cash cycle ↓
P/E ↓
12M momentum
Dec '21Jul '22Jan '23Jul '23Jan '24Jul '24Jan '25Jul '25Jan '26Jul '26Nov '26
Lower rank Higher rank Not enough data

Percentiles use today's listed companies in the sector and need at least 5 peers with a value; grey cells have too few.
ROE is computed from net profit and book value where the source does not report it.

The Health Technology sector page Watch it move against Health Technology in the Observatory

What is the price implying?

~19%annual earnings growth implied by the priceBelow delivered growth

At P/E of 28.6x, a holder earning 12%/yr needs earnings to grow about 18.9%/yr for 10 years, then trade at 15x.

Delivered22.2%/yrEPS, last 10 fiscal years · fitted trend
Gap−3.3 ptsimplied minus delivered
Rank593rdmost demanding of 856

Over time

Implied growth by month (solid) and delivered growth (dashed).

0%22%45% Jan 2019Nov 2026 0%22%45% Jan 2019Nov 2026

Change the assumptions

Exit P/E / return11%12%13%
12x20.4%21.5%22.6%
15x17.9%18.9%20.0%
20x14.6%15.6%16.7%

Drag a slider to test other assumptions

Implied: 18.9%/yr

Looking back

  • Jan 2020Price implied 15%/yr; EPS has since grown 20%/yr (7.0 yrs)
  • Jan 2021Price implied 18%/yr; EPS has since grown 20%/yr (6.0 yrs)
  • Jan 2022Price implied 22%/yr; EPS has since grown 21%/yr (5.0 yrs)

Past comparisons cover only companies listed today (survivorship bias) and say nothing about future outcomes.

“Implied growth” is what the current price would require under our stated assumptions, not what we expect. How this is calculated and the market-wide lists.

What prices imply across Health Technology The market-wide Expectations lists

Key figures

Share Priceclose 9 Nov
₹2502.50
P/E
28.6x
ROCE
24.0%
Market Cap
₹19018 cr
Revenue (TTM)
₹2287 cr
P/S
8.3x
P/B
5.6x
ROE
19.7%
Operating Margin
35.0%
Debt / Equity
0.1x
Promoter Holding
70.6%
12M Momentum
31.0%

52-week range

₹1500.30₹2990.00
67% of the way from its 52-week low to its high

Price risk

1Y volatility
34.1%
Beta vs sector
1-year daily
1.20

Balance sheet & cash

Debt service
no meaningful debt
Cash from profit, 3Y
operating cash flow ÷ net profit
0.77x
Share count, 1Y
unchanged

Are profits backed by cash?

4 of 7checks within range3 near a threshold
Other income reliance15%Within range

Other income as a share of pre-tax profit (trailing twelve months): 14.9%. Bands: below 15%, 15% to 35%, above 35%.

Tax rate19%Within range

Median quarterly effective tax rate over about 2.5 years: 19.0%. Bands: 15% to 35%, 5% to 15% or 35% to 50%, outside 5% to 50%.

Cash conversion0.77xNear threshold

Operating cash flow divided by net profit over the last three fiscal years: 0.77x (cash from operations ₹1,273 cr, net profit ₹1,652 cr). Bands: 0.8x and above, 0.5x to 0.8x, below 0.5x.

Free cash flow5 of 5 yrsWithin range

Fiscal years with positive free cash flow in the last 5: 5. Bands: at least 80% of years, 40% to 80%, below 40%.

Receivable days vs history+21 daysNear threshold

Debtor days are above the median of the previous three fiscal years by 21 days (138 vs 117). Bands: under 15 days, 15 to 45, over 45.

Capital work in progress40% of fixed assetsNear threshold

Capital work-in-progress is 40% of fixed assets. Bands: not rising or up to 30%; rising for three years and above 30%; rising and above 60%.

Payable days+9 days / 2 yrsWithin range

Days payable changed by +9 over two years. Bands: rise of up to 30 days; more than 30 days.

Tap a check to see how it is measured

How to read this

Each check is a named rule with fixed thresholds, not a score. Annual statements are the latest restated figures, so a past year may differ from what was originally reported.

All terms explained in the glossary →

Who has been buying and selling?

  • Over 3 years, FIIs added 2.7 pts; DIIs added 2.3 pts.
  • The number of shareholders rose from 78,068 to 94,385 (+21%) between Sep 2023 and Jun 2026.

Holdings, Jun '26

How each group changed

GroupSep '23Jun '26Change
Promoters70.6%70.6%-0.1 pts
FIIs3.1%5.8%+2.7 pts
DIIs0.2%2.5%+2.3 pts
Public and others26.1%21.2%-4.9 pts

Number of shareholders

94,385shareholders+21% since Sep '23
78k84k90k96k Sep '23Jun '24Mar '25Dec '25Jun '26
Sep '23: 78,068
Dec '23: 79,438
Mar '24: 81,409
Jun '24: 80,411
Sep '24: 96,123
Dec '24: 92,702
Mar '25: 96,387
Jun '25: 94,169
Sep '25: 93,753
Dec '25: 93,705
Mar '26: 93,896
Jun '26: 94,385
 78k84k90k96k Sep '23Sep '24Sep '25Jun '26
Sep '23: 78,068
Dec '23: 79,438
Mar '24: 81,409
Jun '24: 80,411
Sep '24: 96,123
Dec '24: 92,702
Mar '25: 96,387
Jun '25: 94,169
Sep '25: 93,753
Dec '25: 93,705
Mar '26: 93,896
Jun '26: 94,385

Quarterly shareholding as reported, labelled by the quarter it covers (it becomes visible about two months later).
Shareholder counts are only available for recent quarters.

This quarter's smart-money board

What happened next to similar setups

−2.6%typical 12-month return vs the marketNot meaningfully different from the base rate
  • We found 50 past situations where a non-financial company looked like CAPLIN POINT LABORATORIES LTD today on valuation, return on capital, margins, debt, growth, price momentum, size and volatility.
  • Over the following 12 months the middle half of them returned −19% to +27% vs the market, against −3% for all non-financial companies in the same months.
  • The gap against the base rate (+0.2%, 80% range −4.8% to +5.3%) is within what chance and overlapping periods produce.

Where the 50 outcomes landed

−100%−50%0%+50%+100%
VEEDOL · Jun 2021: −58.5% vs market
CONCORDBIO · Jan 2025: −48.6% vs market
BLS · Mar 2025: −39.2% vs market
EMAMILTD · Apr 2025: −33.3% vs market
VINATIORGA · Jun 2025: −32.5% vs market
ARE&M · Jun 2020: −29.9% vs market
ICRA · Aug 2025: −25.4% vs market
GREAVESCOT · Feb 2020: −22.5% vs market
EIHOTEL · Oct 2025: −22.4% vs market
CRISIL · Jul 2025: −22.0% vs market
CERA · Apr 2023: −22.0% vs market
RADICO · Dec 2021: −21.0% vs market
SUMICHEM · Sep 2025: −19.2% vs market
ERIS · May 2020: −18.5% vs market
MANKIND · Jan 2025: −17.8% vs market
KPRMILL · May 2022: −16.3% vs market
FINPIPE · Mar 2020: −9.9% vs market
ECLERX · Sep 2025: −9.9% vs market
AIAENG · Jul 2023: −9.4% vs market
GARFIBRES · Jun 2021: −9.1% vs market
CENTURYPLY · Aug 2022: −6.8% vs market
ELECON · Apr 2024: −5.5% vs market
ATUL · Sep 2020: −5.4% vs market
KAJARIACER · Jun 2021: −3.3% vs market
CARBORUNIV · Oct 2021: −2.9% vs market
AJANTPHARM · Apr 2025: −2.2% vs market
RATNAMANI · Apr 2023: −0.5% vs market
LAOPALA · Nov 2020: +1.1% vs market
LTTS · Jun 2021: +4.3% vs market
BALKRISIND · Feb 2020: +4.4% vs market
POLYCAB · Sep 2021: +6.8% vs market
CARERATING · Oct 2025: +9.2% vs market
COFORGE · Feb 2020: +10.5% vs market
RHIM · May 2022: +11.9% vs market
KEI · Nov 2023: +15.8% vs market
DHANUKA · Mar 2020: +18.0% vs market
KIMS · Jun 2022: +25.7% vs market
LALPATHLAB · Sep 2025: +26.7% vs market
JBCHEPHARM · Jan 2021: +27.6% vs market
SUPREMEIND · May 2020: +27.8% vs market
HSCL · Jun 2025: +30.9% vs market
KFINTECH · Feb 2024: +32.3% vs market
CUMMINSIND · Jul 2023: +32.7% vs market
ADVENZYMES · Mar 2020: +34.6% vs market
MPHASIS · May 2020: +34.6% vs market
BDL · Jun 2022: +37.0% vs market
GRINDWELL · Aug 2021: +59.0% vs market
THYROCARE · Jun 2025: +66.0% vs market
NEWGEN · Jun 2023: +95.5% vs market
PERSISTENT · Dec 2020: +139.5% vs market
Similar setups −2.6%All companies −2.8%← worse than the marketbetter than the market →

Each dot is one past situation (hover or tap for details) · Solid dots are the closest matches, listed below · Shaded is the middle half of all companies in the same months · 1 beyond the range shown, drawn at the edge

Similar setups' median
−2.6%
All companies' median
−2.8%
Beat the market
46% vs 47%

50 past situations · 50 companies · 30 months · 2020–2025

The closest matches

CompanyWhenP/EROCE12M mom.DrawdownNext 12 months
EIHOTEL
Consumer Services		 Oct 2025 36x23% +7%−9% −22%
GREAVESCOT
Producer Manufacturing		 Feb 2020 19x24% +4%−15% −23%
EMAMILTD
Consumer Non-Durables		 Apr 2025 34x32% +28%−26% −33%
ATUL
Process Industries		 Sep 2020 27x28% +53%−12% −5%
BALKRISIND
Consumer Durables		 Feb 2020 27x22% +24%−14% +4%
Show the other 3 matches
CompanyWhenP/EROCE12M mom.DrawdownNext 12 months
FINPIPE
Producer Manufacturing		 Mar 2020 13x21% −20%−36% −10%
AJANTPHARM
Health Technology		 Apr 2025 38x32% +22%−21% −2%
CARBORUNIV
Process Industries		 Oct 2021 56x19% +195%−10% −3%
How reliable is this?

Matched on P/E, P/S, ROCE, operating margin, debt/equity, revenue growth, 12-month momentum, drawdown from 12-month high, size and volatility. Closest on: drawdown from 12-month high, ROCE and 12-month momentum. Not used (unavailable for this company): interest cover. One match per company and at most 7 from any one month.

Independent periods: the matches fall in 5 distinct 12-month windows. Matches from nearby months share the same market conditions, so fewer windows means less evidence.

How this is built

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to CAPLIN POINT LABORATORIES LTD. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

Methodology

How historical analogs are built

Data as of 2026-11-09. Outcome pool: Jan 2020 to Oct 2025.

For every company we look at the situation it is in today (valuation, return on capital, margins, debt, growth, 12-month price momentum, drawdown, size and volatility) and find past company-months that looked most like it. We then show what happened to those past situations over the following 12 months, measured against the ApnaFunda All index and against the base rate. It describes history. It does not predict anything.

What is compared

FeatureWeightNon-financialFinancial
P/E1yesyes
P/S1yes—
P/B1—yes
ROCE1yes—
operating margin1yes—
ROE1—yes
debt/equity0.75yes—
interest cover0.5yes—
revenue growth0.75yesyes
12-month momentum1yesyes
drawdown from 12-month high0.75yesyes
size0.75yesyes
volatility0.5yesyes

Weights were set by judgement before any outcome was looked at and are never tuned on results. Loss-making companies (negative P/E or net profit) are only matched with other loss-making companies. Banks, NBFCs and insurers are compared only with each other and use a different feature set. Every feature is converted, month by month, to its rank among companies in the same pool in that month, so a P/E of 30 in a hot market and a P/E of 22 in a cold one can match if both were equally expensive for their time. Only that month's data is used.

How closeness and the sample are defined

Distance is the weighted root-mean-square gap between the standardised features both companies have. A match needs at least 70% of the query's feature weight, a distance of at most 0.9, and 30 matches at minimum to be shown. We keep up to 50 matches with these exclusions: never the company itself, one match per company (its closest month), and at most 7 from any one calendar month so a single market episode cannot dominate.

Base rate

The base rate is the distribution of 12-month returns, relative to the market, of every eligible company-month in the same pool, with each month weighted to match the months the analogs came from. It answers: how did a random company do in these same months? Because matches from nearby months share the same market conditions, we also report the number of distinct 12-month windows behind a result, and a bootstrap that resamples months decides whether the analog median differs from the base rate at all. "Not meaningfully different" is the usual outcome and the page copy is written for it.

Limits you should know

  • One market period. The outcome pool covers 2020–2025 only (70 months), including the 2020 crash and the 2020–21 rally.
  • Survivorship. Only companies listed today are included. Delisted and bankrupt companies are missing, which flatters past outcomes, particularly for distressed-looking setups.
  • Price return only. Dividends are excluded, and the benchmark is an ApnaFunda market-cap-weighted index of the same listed companies, not an official index.
  • Reporting lag. Fundamentals are matched on an assumed 60-day lag after the quarter end, not on real announcement dates.
  • Pools: non-financial: 98,395 company-months from 2019 companies; financial: 5,659 company-months from 108 companies. 2349 companies currently have a result; the rest are suppressed because too few comparable situations exist.

Does it work? A walk-forward check

The walk-forward check has not been run for this build, so skill is shown as not yet measured.

Disclaimer

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to any company shown. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

What else looks like this?

Companies with the most similar financial profile today, regardless of industry.

ADITYA BIRLA SUN LIFE AMCABSLAMC
Finance
76%similar
market capEPS growth
CRISILCRISIL
Commercial Services
71%similar
revenue growthoperating margin
ORACLE FINANCIAL SERVICES SOFTOFSS
Technology Services
68%similar
revenue growthvolatility
NIPPON LIFE IND ASSET MANAGEMENAM-INDIA
Finance
67%similar
promoter holdingrevenue
NESCONESCO
Producer Manufacturing
66%similar
debt/equityoperating margin
AJANTA PHARMAAJANTPHARM
Health Technology
68%similar
revenue growthdebt/equity
ABBOTT INDIAABBOTINDIA
Health Technology
62%similar
EPS growthoperating margin
INVENTURUS KNOWLEDGE SOLUIKS
Health Technology
61%similar
volatilityoperating margin

Similarity is statistical, based on reported metrics; it does not imply similar business quality or future returns.

What changed?

30 events since May '22

  1. SepPriceVolume reached 22.3x its 50-day median on 2026-09-01; price +7.7% that day.
  2. JunPriceRegained the 2024-12 peak, 3 months after the low.
  3. JunValuationP/E crossed above the 90th percentile of its own history to date (31.1x).
  4. MayPriceVolume reached 31.8x its 50-day median on 2026-05-14; price +9.9% that day.
  5. MarPriceFell 42% from the Dec 2024 peak to the Mar 2026 low.
  6. DecPriceVolume reached 14.1x its 50-day median on 2025-12-30; price -5.4% that day.
  7. AugPriceVolume reached 15.2x its 50-day median on 2025-08-07; price +6.7% that day.
  8. MayPriceVolume reached 5.9x its 50-day median on 2025-05-21; price +5.9% that day.
Show 22 earlier events
  1. MarValuationP/E crossed above the 90th percentile of its own history to date (29.5x).
  2. MarPriceVolume reached 9.8x its 50-day median on 2025-03-21; price +2.0% that day.
  3. OctPriceVolume reached 13.9x its 50-day median on 2024-10-01; price +9.5% that day.
  4. SepPeer rankMoved into the 2nd quartile of Health Technology on EPS growth (from the 3rd quartile).
  5. AugValuationP/E crossed above the 90th percentile of its own history to date (31.6x).
  6. AugPriceVolume reached 48.7x its 50-day median on 2024-08-19; price +16.4% that day.
  7. JunResultsRevenue (TTM) reached a new high of ₹1,694 cr.
  8. JunPeer rankSlipped to the 3rd quartile of Health Technology on EPS growth (from the top quartile).
  9. JunPriceVolume reached 11.9x its 50-day median on 2024-06-10; price +8.1% that day.
  10. NovValuationP/E crossed above the 90th percentile of its own history to date (25.3x).
  11. NovPriceVolume reached 17.2x its 50-day median on 2023-11-10; price +8.4% that day.
  12. AugPriceRegained the 2021-09 peak, 5 months after the low.
  13. AugPriceVolume reached 33.1x its 50-day median on 2023-08-08; price +11.1% that day.
  14. JunResultsRevenue (TTM) reached a new high of ₹1,467 cr.
  15. AprPriceVolume reached 12.5x its 50-day median on 2023-04-19; price +9.1% that day.
  16. MarPriceFell 39% from the Sep 2021 peak to the Mar 2023 low.
  17. MarPriceVolume reached 43.0x its 50-day median on 2023-03-20; price +3.4% that day.
  18. NovPriceVolume reached 7.8x its 50-day median on 2022-11-14; price +6.0% that day.
  19. AugPriceVolume reached 13.2x its 50-day median on 2022-08-01; price +7.2% that day.
  20. JunResultsRevenue (TTM) reached a new high of ₹1,269 cr.
  21. JunPeer rankMoved into the top quartile of Health Technology on EPS growth (from the 3rd quartile).
  22. MayPriceVolume reached 11.1x its 50-day median on 2022-05-19; price +7.8% that day.

Events are generated from the data by fixed rules.
The month shown is when the change became visible in the reported figures, assuming a 60-day lag after each quarter end; it is not an announcement date.

Where price and fundamentals disagree, market-wide Rewind the whole market to any month

Monthly history60 months · 2021-12 to 2026-11
MonthP/ERevenue (TTM)ROEROCEDebt / Equity
2026-1128.6x₹2287 cr19.7%24.0%0.1x
2026-1026.6x₹2287 cr20.1%24.0%0.1x
2026-0931.0x₹2287 cr20.1%24.0%0.1x
2026-0829.8x₹2187 cr19.3%24.0%0.1x
2026-0729.8x₹2187 cr19.3%24.0%0.1x
2026-0631.1x₹2187 cr19.3%24.0%0.1x
2026-0525.1x₹2089 cr23.6%26.0%0.1x
2026-0421.2x₹2089 cr23.6%26.0%0.1x
2026-0318.6x₹2089 cr23.6%26.0%0.1x
2026-0221.9x₹2039 cr22.6%26.0%0.1x
2026-0122.9x₹2039 cr22.6%26.0%0.1x
2025-1223.7x₹2039 cr22.6%26.0%0.1x
2025-1125.7x₹1988 cr21.5%26.0%0.1x
2025-1027.3x₹1988 cr21.5%26.0%0.1x
2025-0926.4x₹1988 cr21.5%26.0%0.1x
2025-0829.7x₹1937 cr20.5%26.0%0.1x
2025-0729.3x₹1937 cr20.5%26.0%0.1x
2025-0630.0x₹1937 cr20.5%26.0%0.1x
2025-0531.7x₹1888 cr24.6%26.0%0.1x
2025-0427.7x₹1888 cr24.6%26.0%0.1x
2025-0329.5x₹1888 cr24.6%26.0%0.1x
2025-0228.1x₹1831 cr23.7%26.0%0.1x
2025-0131.9x₹1831 cr23.7%26.0%0.1x
2024-1238.5x₹1831 cr23.7%26.0%0.1x
2024-1134.9x₹1758 cr23.0%26.0%0.1x
2024-1032.4x₹1758 cr23.0%26.0%0.1x
2024-0930.2x₹1758 cr23.0%26.0%0.1x
2024-0831.6x₹1694 cr22.0%26.0%0.1x
2024-0726.2x₹1694 cr22.0%26.0%0.1x
2024-0624.5x₹1694 cr22.0%26.0%0.1x
2024-0526.0x₹1467 cr22.7%26.0%0.1x
2024-0427.4x₹1467 cr22.7%26.0%0.1x
2024-0326.5x₹1467 cr22.7%26.0%0.1x
2024-0229.9x₹1467 cr22.7%26.0%0.1x
2024-0129.2x₹1467 cr22.7%26.0%0.1x
2023-1227.4x₹1467 cr22.7%26.0%0.1x
2023-1125.3x₹1467 cr22.7%26.0%0.1x
2023-1020.7x₹1467 cr22.7%26.0%0.1x
2023-0920.8x₹1467 cr22.7%26.0%0.1x
2023-0821.3x₹1467 cr22.7%26.0%0.1x
2023-0718.3x₹1467 cr22.7%26.0%0.1x
2023-0616.3x₹1467 cr22.7%26.0%0.1x
2023-0518.9x₹1269 cr24.3%28.0%0.2x
2023-0417.1x₹1269 cr24.3%28.0%0.2x
2023-0315.1x₹1269 cr24.3%28.0%0.2x
2023-0216.5x₹1269 cr24.3%28.0%0.2x
2023-0117.5x₹1269 cr24.3%28.0%0.2x
2022-1218.0x₹1269 cr24.3%28.0%0.2x
2022-1119.1x₹1269 cr24.3%28.0%0.2x
2022-1018.3x₹1269 cr24.3%28.0%0.2x
2022-0918.8x₹1269 cr24.3%28.0%0.2x
2022-0819.7x₹1269 cr24.3%28.0%0.2x
2022-0719.7x₹1269 cr24.3%28.0%0.2x
2022-0618.0x₹1269 cr24.3%28.0%0.2x
2022-0523.2x₹1061 cr25.9%28.0%0.2x
2022-0422.0x₹1061 cr25.9%28.0%0.2x
2022-0321.2x₹1061 cr25.9%28.0%0.2x
2022-0220.8x₹1061 cr25.9%28.0%0.2x
2022-0124.8x₹1061 cr25.9%28.0%0.2x
2021-1226.8x₹1061 cr25.9%28.0%0.2x

Older months are in the live observatory.

Methodology and data notes

Methodology

Methodology and data notes

All figures come from public exchange prices and screener.in financial statements. Quarterly and annual results are shown from 60 days after the period end, so a month never uses a result before it would plausibly have been published. Statements are the latest versions, which may include later restatements.

Sector medians, percentiles and indices use today's listed companies in the sector (survivorship bias). Prices are adjusted for splits and bonus issues; around a corporate action the fundamentals may lag the price by up to a month, and affected sections are hidden.

The return decomposition uses price = P/E × net profit ÷ share count. The reverse DCF uses a fixed 12% cost of equity, a 10-year horizon and a 15x terminal P/E, and is an illustration only. Events, flags and twins follow fixed rules and thresholds described next to each section.

Feedback